Peritoneal CarcinomatosisPeritoneal MetastasesAppendix CancerAppendix NeoplasmColorectal Cancer
Investigational drug(s) / intervention(s)
Whole-body diffusion-weighted magnetic resonance imaging
Whole-body diffusion-weighted magnetic resonance imaging: See arm description.
Study summary
Diffusion-weighted magnetic resonance imaging (DWI/MRI) has been described in recent literature as a highly sensitive and specific modality for the detection of peritoneal metastases PM. It has been demonstrated to be superior to CT for patients with known peritoneal disease from colorectal and gynaecological malignancies as a staging tool for cytoreductive surgery. It was also demonstrated to be superior for the detection of PM for gastric cancer patients otherwise considered with a resectable tumor. However, the literature is scarce on the role of DWI/MRI in the detection of peritoneal recurrence for patients with high-risk features, either colorectal cancer (CRC) or appendiceal neoplasms (AN).
The aim of this study is to prospectively assess the added value of whole-body DWI/MRI (WB-DWI/MRI) to CT and diagnostic laparoscopy for detection of PM in the follow-up of patients presenting with CRC or AN and high-risk features for peritoneal recurrence and evaluate how it correlates with intraoperative findings.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Confirmed diagnosis of colorectal cancer or high-risk appendiceal neoplasm (High grade Appendiceal Mucinous Neoplasm (HAMN), goblet-cell carcinoma or adenocarcinoma).
* No evidence of residual peritoneal disease based on referring surgeon operating report and preoperative imaging.
* At least one high-risk feature for peritoneal recurrence, including:
* Synchronous peritoneal metastases resected at index surgery;
* Synchronous ovarian metastases resected at index surgery;
* Perforated primary tumor.
* No evidence of distant metastases.
* Patient fit for cytoreductive surgery, if required (ECOG 0 or 1).
Exclusion Criteria:
* Unresected synchronous peritoneal metastases at referral.
* Low grade Appendiceal Mucinous Neoplasm (LAMN).
* No high-risk feature for peritoneal recurrence.
* Evidence of distant metastases on preoperative imaging.
* Patient who is unable to have MRI.
* Patient unfit for cytoreductive surgery, if required (ECOG 2 or more).
Primary outcome measure(s)
Peritoneal findings — 24 months The number of cases in which peritoneal findings on MRI matched with surgical exploration.
Early peritoneal recurrence — 36 months The number of cases with early peritoneal recurrence after MRI.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.